Sponsored by James Comer (R)
Office of National Drug Control Policy Reauthorization Act of 2024
Would have renewed the White House drug policy office and its anti-drug grant programs through 2031.
Tradeoff
Would have authorized about $299 million a year for high intensity drug trafficking area (HIDTA) grants through 2031. Would also have added naloxone and other overdose-reversal tools to federal harm reduction programs.
What's in it
The House passed this bill 399-1 on December 5, 2024. The Senate never voted on it before the Congress ended, so the bill expired.
House
Introduced
(Sep 16, 2024)
House
Committee on Oversight and Accountability(Sep 16, 2024)
The bill went to more than one committee at the same time.
House
The committee voted to send it to the floor
Reported 38 - 0(Sep 18, 2024)
House
On Motion to and Pass, as Amended
Passed(Roll #485 · Dec 5, 2024)
399 yeanay 1Senate
Received from the House
on the Judiciary(Dec 9, 2024)
- Jamie Raskin (D-MD)
- John S. Duarte (R-CA)
- Jerrold Nadler (D-NY)
- Jenniffer Rescom. González-Colón (R-PR)
- Stacey E. Plaskett (D-VI)
Passage votes· Dec 5, 2024· 118th Congress · 2023–2025